- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips, Schering plan to partner in optical imaging
Philips and Schering are collaborating in breast imaging, using a fluorescent dye developed by Schering and an experimental optical scanner under construction by Philips. The two technologies will be merged as part of a phase I clinical trial that could begin some time next year.
Philips and Schering are collaborating in breast imaging, using a fluorescent dye developed by Schering and an experimental optical scanner under construction by Philips. The two technologies will be merged as part of a phase I clinical trial that could begin some time next year.
The fluorescent dye omocianine will be injected into the bloodstream, absorbing energy from a pulsed laser. The blood pool agent will then fluoresce, transmitting light back to the Philips scanner for reconstruction into images. The presence of abnormal vascular beds apparent in the images will indicate tumors, according to Philips.
A commercial device is several years away, as the safety and efficacy of the device and imaging agent must be documented to win FDA approval for marketing in the U.S. The clinical trials planned for next year will begin to provide that documentation.
In the meantime, Philips and Schering may expand their alliance to cover other imaging technologies and contrast agents that might lead to synergies, according to the companies. They have agreed to split equally all research and development costs as well as all future revenues from the contrast agents, medical equipment, and related services related to this partnership.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
